ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(5), P. 4373 - 4386
Published: Feb. 19, 2023
Therapeutic
proteins
are
playing
increasingly
important
roles
in
treating
numerous
types
of
diseases.
However,
oral
administration
proteins,
especially
large
ones
(e.g.,
antibodies),
remains
a
great
challenge
due
to
their
difficulties
penetrating
intestinal
barriers.
Herein,
fluorocarbon-modified
chitosan
(FCS)
is
developed
for
efficient
delivery
different
therapeutic
particular
such
as
immune
checkpoint
blockade
antibodies.
In
our
design,
mixed
with
FCS
form
nanoparticles,
lyophilized
appropriate
excipients,
and
then
filled
into
enteric
capsules
administration.
It
has
been
found
that
could
promote
transmucosal
its
cargo
protein
via
inducing
transitory
rearrangement
tight
junction
associated
between
epithelial
cells
subsequently
release
free
blood
circulation.
shown
at
5-fold
dose
anti-programmed
cell
death
protein-1
(αPD1)
or
combination
anti-cytotoxic
T-lymphocyte
antigen
4
(αCTLA4)
using
this
method
achieve
comparable
antitumor
responses
achieved
by
intravenous
injection
corresponding
antibodies
various
tumor
models
and,
more
excitingly,
result
significantly
reduced
immune-related
adverse
events.
Our
work
successfully
demonstrates
the
enhanced
antibody
drugs
systemic
may
revolutionize
future
clinical
usage
therapeutics.
Advanced Drug Delivery Reviews,
Journal Year:
2022,
Volume and Issue:
182, P. 114097 - 114097
Published: Jan. 7, 2022
The
oral
administration
of
therapeutic
peptides
and
proteins
is
favoured
from
a
patient
commercial
point
view.
In
order
to
reach
the
systemic
circulation
after
administration,
these
drugs
have
overcome
numerous
barriers
including
enzymatic,
sulfhydryl,
mucus
epithelial
barrier.
development
formulations
for
therefore
necessary.
Among
most
promising
formulation
approaches
are
lipid-based
nanocarriers
such
as
oil-in-water
nanoemulsions,
self-emulsifying
drug
delivery
systems
(SEDDS),
solid
lipid
nanoparticles
(SLN),
nanostructured
carriers
(NLC),
liposomes
micelles.
As
lipophilic
character
can
be
tremendously
increased
by
formation
hydrophobic
ion
pairs
(HIP)
with
counter
ions,
they
incorporated
in
phase
carriers.
Since
gastrointestinal
(GI)
peptidases
well
sulfhydryl
compounds
glutathione
dietary
too
hydrophilic
enter
carriers,
peptide
or
protein
protected
towards
enzymatic
degradation
unintended
thiol/disulfide
exchange
reactions.
Stability
lipases
provided
use
excipients
that
not
just
poorly
degraded
enzymes.
Nanocarriers
size
<200
nm
mucoinert
surface
PEG
zwitterionic
surfaces
exhibit
high
permeating
properties.
Having
reached
underlying
absorption
membrane,
enable
paracellular
lymphatic
uptake,
induce
endocytosis
transcytosis
simply
fuse
cell
membrane
releasing
their
payload
into
circulation.
Numerous
vivo
studies
provide
evidence
potential
systems.
Within
this
review
we
an
overview
about
different
delivery,
highlight
progress
made
on
them
discuss
strengths
weaknesses
comparison
other
technologies.
Advanced Pharmaceutical Bulletin,
Journal Year:
2022,
Volume and Issue:
13(3), P. 446 - 460
Published: Sept. 18, 2022
Nanostructured
Lipid
Carriers
(NLC)
are
nano-sized
colloidal
drug
delivery
system
that
contains
a
lipid
mixture
consisting
of
both
solid
and
liquid
lipids
in
their
core.
This
Lipid-Based
Nanosystem
is
introduced
as
biocompatible,
non-toxic,
safe
nano-drug
compared
to
polymeric
or
metallic
nanoparticles.
Due
its
safety,
stability,
high
loading
capacity
other
lipid-based
nanocarriers,
NLC
gained
the
attention
researchers
formulate
effective
carriers.
The
ability
increase
solubility
permeability
while
encapsulating
lipidic
shell
makes
them
an
ideal
carrier
for
through
difficult-to-achieve
routes.
Surface
modification
use
various
additives
result
targeting
increased
residence
time.
With
such
qualities,
NLCs
can
be
used
treat
variety
diseases
cancer,
infections,
neurodegenerative
diseases,
hypertension,
diabetes,
pain
management.
review
focuses
on
recent
developments
being
made
deliver
drugs
genes
different
routes
via
these
nanocarriers.
Here,
we
also
discuss
about
historical
background,
structure,
types
commonly
employed
techniques
manufacturing
Future Drug Discovery,
Journal Year:
2022,
Volume and Issue:
4(2)
Published: June 1, 2022
Peptides
have
traditionally
been
perceived
as
poor
drug
candidates
due
to
unfavorable
characteristics
mainly
regarding
their
pharmacokinetic
behavior,
including
plasma
stability,
membrane
permeability
and
circulation
half-life.
Nonetheless,
in
recent
years,
general
strategies
tackle
those
shortcomings
established,
peptides
are
subsequently
gaining
increasing
interest
drugs
unique
ability
combine
the
advantages
of
antibodies
small
molecules.
Macrocyclic
a
special
focus
development
efforts
address
so
called
‘undruggable’
targets
characterized
by
large
flat
protein
surfaces
lacking
binding
pockets.
Here,
main
developed
date
for
adapting
clinical
use
summarized,
which
may
soon
help
usher
an
age
highly
shaped
peptide-based
therapeutics.
limited
is
still
overcome
before
peptide
therapeutics
will
be
broadly
accepted.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(14), P. 13044 - 13061
Published: July 6, 2023
Oral
drug
administration
has
been
a
popular
choice
due
to
patient
compliance
and
limited
clinical
resources.
Orally
delivered
drugs
must
circumvent
the
harsh
gastrointestinal
(GI)
environment
effectively
enter
systemic
circulation.
The
GI
tract
number
of
structural
physiological
barriers
that
limit
bioavailability
including
mucus,
tightly
regulated
epithelial
layer,
immune
cells,
associated
vasculature.
Nanoparticles
have
used
enhance
oral
drugs,
as
they
can
act
shield
prevent
early
degradation
while
also
increasing
uptake
transport
across
intestinal
epithelium.
Evidence
suggests
different
nanoparticle
formulations
may
be
transported
via
intracellular
mechanisms
cross
Despite
existence
significant
body
work
on
nanoparticles,
many
key
questions
remain:
What
causes
poor
drugs?
factors
contribute
ability
barriers?
Do
properties
such
size
charge
influence
type
endocytic
pathways
taken?
In
this
Review,
we
summarize
components
types
nanoparticles
developed
for
delivery.
particular,
focus
various
in
internalization
or
cargo
translocation
Understanding
gut
barrier,
characteristics,
lead
development
more
therapeutically
useful
carriers.
Acta Pharmaceutica Sinica B,
Journal Year:
2023,
Volume and Issue:
13(9), P. 3659 - 3677
Published: Feb. 28, 2023
Peptide‒drug
conjugates
(PDCs)
are
drug
delivery
systems
consisting
of
a
covalently
coupled
to
multifunctional
peptide
via
cleavable
linker.
As
an
emerging
prodrug
strategy,
PDCs
not
only
preserve
the
function
and
bioactivity
peptides
but
also
release
drugs
responsively
with
property
linkers.
Given
ability
significantly
improve
circulation
stability
targeting
in
vivo
reduce
toxic
side
effects
drugs,
have
already
been
extensively
applied
delivery.
Herein,
we
review
types
mechanisms
peptides,
linkers
used
construct
PDCs,
summarize
clinical
applications
challenges
PDC
drugs.
